why choose us

First received: September 02, 2022

Clinical Trial: PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-small Cell Lung Cancer (NSCLC)

Study Type: INTERVENTIONAL


Official Title: A Phase II Study of PCSK9 Inhibitor Alirocumab and PD-1 Inhibitor Cemiplimab in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung Cancer: TOP2201

Brief Summary: PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules.This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can generate anti-tumor activity and clinical responses in patients with metastatic lung cancer who have progressed on first line immune checkpoint blockade therapy.

Read more